Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers Sells 6,983 Shares

Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the sale, the executive vice president now directly owns 29,308 shares in the company, valued at approximately $2,660,580.24. The trade was a 19.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Wendy Carruthers also recently made the following trade(s):

• On Tuesday, October 1st, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The stock was sold at an average price of $83.86, for a total transaction of $585,594.38.

Boston Scientific Trading Up 0.4 %

Boston Scientific stock traded up $0.34 during mid-day trading on Wednesday, hitting $90.81. The company’s stock had a trading volume of 2,059,551 shares, compared to its average volume of 6,025,355. The stock has a market cap of $133.84 billion, a PE ratio of 74.77, a P/E/G ratio of 2.66 and a beta of 0.80. Boston Scientific Co. has a one year low of $53.93 and a one year high of $91.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The company has a 50 day moving average of $86.97 and a 200-day moving average of $81.03.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business’s revenue was up 19.3% compared to the same quarter last year. During the same period last year, the business posted $0.50 EPS. On average, research analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Dunhill Financial LLC increased its holdings in Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 152 shares during the period. Triad Wealth Partners LLC purchased a new position in shares of Boston Scientific during the 2nd quarter worth $26,000. Values First Advisors Inc. acquired a new position in Boston Scientific in the third quarter valued at approximately $28,000. E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of Boston Scientific during the 3rd quarter worth about $30,000. Finally, Capital Performance Advisors LLP purchased a new stake in Boston Scientific in the third quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BSX. Sanford C. Bernstein raised their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. BTIG Research increased their target price on Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Citigroup lifted their price target on Boston Scientific from $92.00 to $98.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. Mizuho raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Finally, StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $93.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.